Cangene Corp to fund Alzheimer's research

Guest Contributor
November 29, 2011

Cangene Corp has signed an MOU with the Univ of British Columbia to develop the research of Dr Neil Cashman, science director of PrioNet Canada and holder of the Canada Research Chair in neurodegeneration and protein misfolding at UBC. Winnipeg-based Cangene became interested in Cashman's work when a research team led by Cashman discovered a way to target amyloid beta oligomers responsible for the progression of Alzheimer's while sparing normal amyloid beta molecules. The early-stage discovery could form the basis of safe immunotherapy infusion, leading to a Canadian-made therapy for the disease. The agreement between Cangene and Cashman's PrioNet research team was facilitated by UBC's University-Industry Liaison Office....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.